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Abstract 
Background: Acute kidney injury (AKI) is a common complication after cardiac surgery. Currently, prediction of AKI 
with classical tools remains uncertain. Therefore, it was the aim of the present study to evaluate two new urinary bio‑
markers—insulin‑like growth factor‑binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases‑2 (TIMP‑2) in 
patients after coronary artery bypass surgery (CABG).
Methods: In a prospective cohort study, 60 consecutive patients undergoing isolated on‑pump CABG were enrolled. 
Urine samples collected every 12 h in the postoperative course were analyzed for the product of TIMP‑2 and IGFBP7. 
Urinary output, serum creatinine and estimated glomerular filtration rate (eGFR) were recorded simultaneously. 
Primary clinical endpoint was the development of AKI stage 2 or 3 according to the classification of the KDIGO within 
48 h after surgery.
Results: 48 male and 12 female patients with a mean age of 69.61 ± 8.4 years were included. 19 patients developed 
an AKI (31.6 %), six patients met the endpoint with AKI 2 or 3 (10 %). Urinary [TIMP‑2]*[IGFBP7] increased significantly 
as early as 4 h after CABG in patients with AKI 2/3 (1.83 ± 2.15 vs. 0.23 ± 0.45, p < 0.05) whereas serum creatinine 
did not increase until 48 h after surgery. The diagnostic accuracy of [TIMP 2]*[IGFBP7] on day one after surgery for 
the prediction of AKI 2/3 was significantly better (sensitivity 0.89, specificity 0.81, AUC 0.817, 95 % CI 0.622–1.0 SE 
0.099, p = 0.022, cut‑off 0.817) than for serum creatinine (AUC 0.359, sensitivity 0.50, specificity of 0.52, cut‑off value 
1.17 mg/dl) and eGFR.
Conclusion: Urinary [TIMP‑2]*[IGFBP7] represents a sensitive and specific biomarker to predict moderate to severe 
AKI very early after CABG. Analyses from our ongoing larger study are necessary to confirm these findings and prob‑
ably increase sensitivity and specificity.
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Background
Acute kidney injury (AKI) is a common and serious com-
plication after coronary artery bypass grafting (CABG). 
According to current definitions, AKI occurs in up to 
40 % of all patients undergoing cardiac surgery [1]. AKI 
requiring renal replacement therapy has an incidence of 
approximately 1–5 % [1]. The development of a postop-
erative AKI is associated with a more complicated clini-
cal course and with an increased mortality of 15–30  %. 
Moreover, even slight changes of renal function are con-
sidered as an independent predictor of 30-day mortality 
[2]. Full recovery of renal function is only observed in 
50 % of surviving patients [3, 4]. Thus, due to its signifi-
cance, the term cardiac surgery-associated acute kidney 
injury (CSA AKI) was established. Risk assessment for 
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AKI is recommended by clinical practice guidelines but 
remains imprecise mainly due to very limited sensitivity 
and specificity of early diagnostic tests available for AKI. 
Although serum creatinine is known to be an inadequate 
and delayed marker of acute changes in renal function, it 
is currently accepted as “gold standard” to diagnose AKI 
due to the lack of other reliable biomarkers. Obviously, 
there is a clear need for sensitive and specific biomarkers 
allowing early identification of patients with high risk for 
AKI to initiate preventive or therapeutic interventions 
[5–7].
Tissue inhibitor of metalloproteinases-2 (TIMP-2) and 
insulin-like growth factor binding protein 7 (IFGBP7) have 
recently been suggested as promising tools for the early 
detection of AKI in critically ill patients [8]. Both proteins 
are inducers of the G1 cell cycle arrest, considered as a key 
mechanism of AKI. In the Sapphire study enrolling 744 
critically ill medical and surgical subjects with a moder-
ate–severe AKI occurring in 14 % of patients, the combi-
nation of TIMP-2 and IGFBP7 was significantly superior 
to all other existing markers of AKI with an AUC of 0.80 
and also better than TIMP–2 (AUC 0.76) and IGFBP7 
(AUC 0.79) alone [9]. Others could confirm these findings 
showing that urinary [TIMP-2]*[IGFBP7] greater than 0.3 
(ng/ml)2/1000 is able to identify patients at risk for immi-
nent AKI [10]. In addition, urinary [TIMP-2]*[IGFBP7] is 
able to predict AKI and renal recovery early after cardiac 
surgery in a subgroup of patients with a high risk for the 
development of AKI defined by a high Cleveland Foun-
dation Score [11]. Therefore, it was the aim of the pre-
sent study to analyze the postoperative course of [TIMP 
2]*[IGFBP7] to evaluate a new diagnostic approach for 
early detection of AKI in patients after isolated CABG.
Methods
Patients
The present study was approved by the Institutional Ethic 
Review Board and informed consent from the patient or 
the patient’s next of kin was obtained. Sixty consecutive 
patients (minimum age: 18 years) scheduled for elective 
on-pump CABG due to severe coronary artery disease 
between January 2014 and October 2014 were consecu-
tively recruited during their pre-admission attendance 
to participate in the study. We used the Standards for 
Reporting of Diagnostic Accuracy (STARD) statement 
for planning and conducting the study and preparing the 
manuscript [12].
Surgical procedure
Surgical revascularization was performed in all patients 
by using hypothermic cardiopulmonary bypass with car-
dioplegic arrest and median sternotomy as described pre-
viously [13]. Briefly, cannulation of the ascending aorta 
and two-stage venous cannulation was performed and 
standard nonpulsatile cardiopulmonary bypass (CPB) 
technique with a membrane oxygenator was initiated. 
During CPB, moderate hemodilution with a hematocrit 
between 20 and 25  % using mild systemic hypothermia 
(32 °C) was maintained. Myocardial protection was per-
formed using anterograde cold crystalloid Bretschneider 
solution (Custodiol, Köhler Chemie GmbH, Bensheim, 
Germany) for cardioplegic arrest with additional topi-
cal cooling and single aortic crossclamping for all distal 
anastomoses.
Biomarker measurements
Urine and blood samples for biomarker analysis were 
obtained 4  h after surgery and then every 12  h until 
discharge from ICU/IMC or for a maximum of 4  days, 
respectively. TIMP-2 and IGFBP7 in the urine were 
measured with the commercially available and FDA-
approved NephroCheck™ Test (Astute Medical, San 
Diego, CA, USA)—a point-of-care test kit developed 
to measure and calculate the product of [TIMP-2] and 
[IGFBP7] concentration in the urine. Physicians in charge 
were blinded for the cell cycle arrest biomarker levels as 
well as laboratory investigators were blinded to clinical 
outcomes. Glomerular filtration rate was calculated with 
the Cockcroft–Gault formula (estimated Glomerular fil-
tration rate = eGFR).
Definition of endpoint and outcomes
AKI stage was determined daily on the basis of diuresis 
rate and serum creatinine concentration according to the 
Kidney Disease: Improving Global Outcomes classifica-
tion (KDIGO) as follows [14]:
AKI 1 increase of serum creatinine by ≥0.3  mg/dl 
(≥26.4  µmol/L) or increase to ≥150–200  % from 
baseline or urine output <0.5 ml/kg/h for >6 h;
AKI 2 increase of serum creatinine to >200–300 % from 
baseline and/or urine output <0.5 ml/kg/h for >12 h;
AKI 3 increase of serum creatinine to >300  % 
from baseline or serum creatinine ≥4.0  mg/dl 
(≥354  µmol/L) after a rise of at least 44  µmol/L or 
treatment with renal replacement therapy and/or 
urine output <0.3  ml/kg/h for >24  h or anuria for 
12 h.
The primary endpoint was the new occurrence of acute 
kidney injury stage 2 or 3 within 48 h after surgery. This 
observation period was chosen because prior studies 
have shown that AKI occurs within the first 24–72 h after 
CABG in the majority of cases.
Sepsis and septic shock was defined according to the 
definition issued by the Surviving Sepsis Campaign [15]. 
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Shock was distinguished as cardiogenic shock (low cardiac 
output syndrome) or septic shock. Low cardiac output syn-
drome (LCOS) was defined as the need for an intra-aortic 
balloon pump (IABP) in the operating room (to be weaned 
from cardiopulmonary bypass) or in the intensive care unit 
because of hemodynamic compromise or the need for ino-
tropic medication (epinephrine >0.25  µg/kg BW/min or 
milrinone >1.5 mg/h) to maintain systolic blood pressure 
greater than 90  mmHg and cardiac output index greater 
than 2.2 l/min/m2 for at least 30 min in the intensive care 
unit, after optimizing preload and afterload, correction of 
serum electrolyte, and blood gas abnormalities.
Sample size calculation
The aim of the present study was to proof the hypothesis 
that mean urine [TIMP-2]*[IGFBP7] levels in patients 
with AKI differ significantly to patients without AKI 
within the first 24 h after surgery.
Therefore, a one-tailed power analysis based on the 
available published data on [TIMP-2]*[IGFBP7] in the 
adult cardiothoracic population was performed to cal-
culate the sample size. We aimed to detect a difference 
of one unit in [TIMP-2]*[IGFBP7] levels with a standard 
deviation of 0.8 units [10]. Expected incidence of AKI 2–3 
was 10 %. With a given probability of type I error (α) of 
0.05, and a power (1 − β) of 0.9, sample size calculation 
revealed a required minimum size of 60 patients at total.
Statistical analysis
Statistical analyses were performed with SPSS Statistics 
19 (IBM, Chicago, IL). Continuous data were expressed 
as mean  ±  SD; categorical data were expressed as per-
centage. Comparisons between two groups were carried 
out using unpaired Student’s t test for normally or the 
Mann–Whitney Rank Sum Test for non-normally distrib-
uted data. Multiple groups were compared with ANOVA. 
Statistical significance was assumed for a p value <0.05. 
To measure the sensitivity and specificity of urinary 
[TIMP-2]*[IGFBP7] at different cut-off values, a conven-
tional receiver operating characteristic (ROC) curve was 
generated. The optimal cut-off level was defined by the 
largest sum of sensitivity and specificity. Comparison of 
ROC curves was performed with the DeLong-Test.
Results
Patients’ characteristics
60 patients undergoing isolated first-time CABG were 
included in this study (see Fig. 1). AKI of any stage within 
Fig. 1 CONSORT (Consolidated Standards of reporting trials) 2010 flow diagram
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48  h after surgery developed in 19 patients (31.7  %): 
AKI was classified as stage 1 according to KDIGO in 13 
patients (21.7  %) and as stage 2 in one patient (1.7  %). 
Five patients (8.3  %) suffered from AKI stage 3. All of 
them required renal replacement therapy (RRT) (8.3 %).
The distributions of applied criteria for AKI staging 
on the basis of serum creatinine or diuresis are given in 
Table 1. Nine patients were defined as patients with AKI 
primarily on the basis of increased serum creatinine con-
centration, and ten patients first reached the threshold of 
a low diuresis rate.
Pre-procedural characteristics as well as operative 
variables and postoperative outcomes of patients suf-
fering from AKI 2/3 compared to those without signifi-
cant postoperative renal dysfunction (KDIGO 2/3) are 
summarized in Table  2. Patients with renal impairment 
were significantly older than those without (76.2  ±  3.9 
vs. 68.8  ±  9.1, p  =  0.003). Preoperative renal function 
assessed by serum creatinine and eGFR showed no differ-
ence between the two groups. Other demographics and 
prevalence of relevant comorbidities were comparable 
between both groups. Patients with a moderate–severe 
AKI suffered from a complicated and prolonged post-
operative course: compromised hemodynamics corre-
sponding to shock was observed in five patients with AKI 
2/3 (83.3 %) and only in six (11.1 %) patients with AKI 0/1 
(p  <  0.001). In addition, incidence of sepsis was higher 
in patients with moderate to severe AKI [5 (83.3  %) vs. 
3 (5.6 %), p < 0.001]. Consecutively, among the AKI 2/3 
group ICU stay tended to be longer without reaching sta-
tistical significance (ICU stay: 9.7 days ± 6.4 vs. 5.5 ± 7.6, 
p =  n.s.). Hospital mortality was significantly higher in 
patients with AKI 2/3 [3 (50.0 % vs. 0 (0 %), p < 0.001]. 
Among the three survivors with AKI2/3, renal function 
recovered within 6 months after surgery without need for 
long-term RRT.
Postoperative course of biomarkers
The postoperative course of serum creatinine, eGFR and 
urinary [TIMP-2]*[IGFBP7] for patients with AKI stage 2/3 
and those with no or mild AKI is illustrated in Fig. 2. No sig-
nificant rise in urinary [TIMP-2]*[IGFBP7] was observed in 
patients with AKI 0/1 at any time indicating that surgical 
myocardial revascularization per se has no influence on the 
investigated G1 cell cycle arrest biomarkers.
In patients developing AKI 2/3 within the 48 postop-
erative hours, [TIMP-2]*[IGFBP7] increased significantly 
already 4 h after surgery compared to patients with AKI 
0/1. Notably, a maximum on the 3rd day with an increase 
to 57.4 ± 32.8 (ng/ml)2/1000 could be observed.
In patients with AKI 0/1, serum creatinine as well as 
eGR remained stable at all times with no significant undu-
lations over time. In contrast, in patients with AKI 2/3, 
elevated serum creatinine levels could be observed from 
postoperative day (POD) 2 to POD 4 with a maximum of 
2.6 ± 1.1 mg/dl as well as elevated eGFR on POD 3 and 4.
Table 1 Classification criteria for staging of AKI






1 13 (21.7 %) 8 5
2 1 (1.7 %) 1 0
3 5 (8.3 %) 0 5
All (1–3) 19 (31.7 %) 9 10
Table 2 Patient characteristics of patients with AKI KDIGO 
≥2 compared to patients with no or mild AKI (KDIGO 0–1)
COPD chronic obstructive pulmonary disease, SAPS Simplified Acute Physiology 







Age (years) 76.2 ± 3.9 68.8 ± 9.1 0.003
Male gender (n, %) 5 (83.3) 43 (79.6) n.s.
Weight (kg) 77.8 ± 11.1 83.7 ± 17.7 n.s.
Height (cm) 174.3 ± 9.2 171.8 ± 8.3 n.s.
CPB time (min) 113.3 ± 41.8 102.1 ± 47.3 n.s.
Preoperative Creatinine 
(mg/dl)
1.01 ± 0.17 1.14 ± 0.23 n.s.
Preoperative eGFR  
(ml/min/1.73 m2)
73.5 ± 13.9 65.0 ± 17.5 n.s.
SAPS 30.8 ± 11.6 24.9 ± 13.8 n.s.
Diuresis on the day of CABG 
(ml/kgBW/h)
1.30 ± 0.33 0.92 ± 0.69 n.s.
Diuresis on POD 1  
(ml/kgBW/h)
1.69 ± 0.66 1.27 ± 0.49 n.s.
Fluid balance on the day  
of surgery (ml)
2843.0 ± 973.8 2354.2 ± 867.5 n.s.
TISS‑28 26.0 ± 6.2 19.7 ± 10.4 n.s.
Comorbidities (n, %)
 MI within 6 months 3 (50.0) 13 (24.1) n.s.
 Heart failure NYHA ≥3 1 (16.7) 3 (5.6) n.s.
 Hypertension 4 (66.7) 49 (90.7) n.s.
 Smoking 3 (50.0) 21 (38.9) n.s.
 Diabetes 2 (33.3) 19 (35.2) n.s.
 COPD 1 (16.7) 7 (12.9) n.s.
 Atrial fibrillation 4 (66.7) 21 (38.9) n.s.
 Peripheral artery disease 1 (16.7) 17 (31.5) n.s.
 Shock (n, %) 5 (83.3) 6 (11.1) <0.001
 Sepsis (n, %) 5 (83.3) 3 (5.6) <0.001
 ICU stay (days) 9.7 ± 6.4 5.5 ± 7.6 n.s.
 Hospital mortality (n, %) 3 (50.0) 0 (0) <0.001
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Distribution of biomarkers measured on POD 1 after 
surgery according to the KDIGO classification is shown 
in Fig. 3. Urinary [TIMP-2]*[IGFBP7] values in patients 
with AKI 3 (median 0.92, range 0.13–5.93) were signifi-
cantly higher than in patients with AKI 0 (median 0.065, 
range 2.69) or AKI 1 (median 0.23, range 0.02–0.53). 
Accordingly, patients with AKI 2 or 3 showed signifi-
cantly higher values for [TIMP-2]*[IGFBP7] than patients 
with AKI 0–1 (median 1.29, range 0.13–5.93 vs. 0.10, 
range 0.02–2.69, p < 0.05).
In contrast, serum creatinine as well as eGFR levels did 
not differ significantly between subgroups stratified by 
KDIGO.
Prediction of AKI with biomarkers
Using ROC analyses, preoperative serum creatinine 
(AUC 0.329, 95 % CI 0.131–0.527, SE 0.101, p = 0.127), 
preoperative eGFR (AUC 0.654, 95 % CI 0.446–0.862, SE 
0.106, p = 0.219), as well as serum creatinine measured 
4  h after surgery (AUC 0.362, 95  %CI 0.165–0.559, SE 
0.100, p = 0.274) did show low predictive values for AKI 
stage 2/3 (see Fig. 4).
eGFR 4  h after CABG showed moderate predictive 
capacity (AUC 0.616, 95  % CI 0.463–0.768, SE 0.78, 
p =  0.359). In contrast, diagnostic accuracy for urinary 
[TIMP-2]*[IGFBP7] 4  h after CABG was more reli-
able with an AUC 0.861 (95  % CI 0.717–1.0, SE 0.073, 
Fig. 2 Postoperative course of [TIMP‑2]*[IGFBP7] (a) serum creatinine (b) and (c) eGFR in patients with AKI ≥2 compared to patients with AKI ≤1
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Fig. 3 Boxplots of biomarker values on postoperative day 1 after CABG grouped by KDIGO stage. a Serum creatinine, b eGFR, c urinary [TIMP 
2]*[IGFBP7]
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p  =  0.04), a sensitivity of 0.83 and a specificity of 0.67 
when using a cut-off value of 0.15 (Fig. 4).
On the 1st postoperative day, setting a cut-off value 
of 1.16 mg/dl for serum creatinine revealed a sensitivity 
and specificity of 0.67 and 0.57, respectively (AUC 0.693, 
95 % CI 0.448–0.939, SE 0.088, p = 0.128). eGFR on POD 
1 showed inferior predictive properties with an AUC of 
0.307 (95 %CI 0.091–0.523, SE 0.110, p = 0.128).
In contrast, [TIMP-2]*[IGFBP7] on postoperative day 1 
showed a higher sensitivity and specificity (0.80 and 0.81, 
respectively), using a cut-off value of 0.89 (AUC 0.869, 
95  % CI 0.696–1.0 SE 0.099, p =  0.04). Urinary [TIMP 
Fig. 4 Receiver operator characteristic (ROC) curve for the prediction of AKI 2–3. a Preoperative serum creatinine and eGFR, b urinary [TIMP‑
2]*[IGFBP7], eGFR and serum creatinine 4 h after CABG. c urinary [TIMP‑2]*[IGFBP7], eGFR and serum creatinine on postoperative day 1 after CABG. d 
Maximum urinary [TIMP‑2]*[IGFBP7], eGFR and serum creatinine during the first 24 h after CABG
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2]*[IGFBP7] maximum values within 24  h after surgery 
were associated with a comparable sensitivity (0.83) and 
specificity (0.78) (AUC 0.838, 95  % CI 0.632–1.0, SE 
0.105, p = 0.007, cut-off 0.89) with maximum serum cre-
atinine and lowest eGFR being associated with a lower 
sensitivity and specificity. Table  3 summarizes the pre-
dictive values of postoperative [TIMP 2]*[IGFBP7] con-
centrations at three cut-offs: In addition to the optimal 
cut-off level from our ROC analyses defined by the largest 
sum of sensitivity and specificity, we applied previously 
published cut-off points from the Sapphire study: one 
cut-off with the highest sensitivity [0.3 (ng/ml)2/1000)] 
and one with the highest specificity [2.0 (ng/ml)2/1000].
Discussion
In critically ill patients, cardiac surgery with the use of 
CPB is the second most common cause of AKI after sep-
sis, with approximately 1–5 % of patients requiring RRT 
[16]. AKI in the cardiothoracic population is associated 
with a significant increase of morbidity and mortality, as 
well as prolonged length of ICU and hospital stay [1].
In the absence of other appropriate alternatives, the use 
of serum creatinine as standard diagnostic test for acute 
kidney injury is commonly accepted among intensivists, 
despite its known major limitation: Renal function must 
be impaired more than 50 % before an elevation in serum 
creatinine can be detected [17]. In addition, serum cre-
atinine does not accurately depict kidney function and 
rapidly changing glomerular fraction rate (GFR) until a 
steady state has been reached [17]. Among other short-
comings, serum creatinine levels do not only dependent 
on excretion through glomerular filtration, but also 
on production mainly by muscle cells and secretion via 
tubular cells. Because of this, conditions that affect mus-
cle mass and tubular secretion (such as age, gender, race, 
and level of GFR) may influence the baseline level and the 
degree of rise in serum creatinine [17]. Moreover, other 
specific conditions of cardiac surgery with extracorpor-
eal circulation, e.g., the CPB induced hemodilution with 
a decrease in serum creatinine concentration cumber 
the creatinine-based diagnosis of AKI [18]. Experimen-
tal studies indicate that specific preventive or therapeutic 
strategies might be able to reduce AKI-associated mor-
bidity and mortality without showing comparable posi-
tive results in the clinical setting [19]. This discrepancy 
might at least partly be explained by the inability to iden-
tify AKI at a very early stage. Although Cystatin C and 
NGAL seem to be reliable in selected patient cohorts and 
automated assay methods are commercially available, the 
value of these two promissing biomarkers in the early 
diagnosis of AKI remains controversial [20–22].
Taken together, there is no biomarker available for early 
and reliable detection of AKI, in particular after cardiac 
surgery, with adequate sensitivity and specificity. Recent 
studies focused on combinations of biomarkers includ-
ing urinary insulin-like growth factor-binding protein 7 
(IGFBP-7) and tissue inhibitor of metalloproteinases-2 
(TIMP-2). This takes into account different pathophysi-
ological mechanisms and, thus, different time courses of 
biomarker release.
IGFBP7 and TIMP-2 are inducers of the G1 cell cycle 
arrest found in renal tubular cells being considered as a 
key mechanism of AKI. They have recently emerged as 
potential novel markers for risk stratification and early 
identification of kidney stress. In the multicenter obser-
vational Discovery study, a total of 300 potential bio-
markers for the detection of AKI were evaluated in a 
heterogeneous group of 522 patients at high risk of AKI 
[9]. The results for IGFBP7 and TIMP-2 were better than 
for any other investigated biomarker (including NGAL, 
KIM-1, and IL-18) with increased sensitivity and specific-
ity when used as combination compared to its single use 
(AUC of 0.80 vs. 0.76 and 0.79 alone). Whereas neither 
TIMP-2 nor IGFBP7 was elevated in patients without 
AKI being unaffected by important co-morbidities such 
as chronic kidney disease, diabetes, and sepsis, patients 
with a [TIMP-2]*[IGFBP7] greater than 0.3 had seven 
times the risk for AKI.
A follow-up trial—the Opal-trial—using identical 
enrolment criteria replicated the results of the Discovery 
study confirming TIMP-2 and IGFBP7 to have better per-
formance than existing markers. Sensitivity and specificity 
of two cut-off values demonstrated the suitability of these 
cell cycle arrest markers for clinical application [23].
Table 3 Analysis of  applying best and  previously pub-
lished cut-off points of  urinary [TIMP–2]*[IGFBP7] for  the 
prediction of AKI KDIGO 2/3
AKI acute kidney injury, AUC area under the curve, IGFBP7 insulin-like growth 
factor-binding protein 7, KDIGO Kidney Disease: Improving Global Outcomes, 
RRT renal replacement therapy, TIMP-2 tissue metalloproteinase-2
a Defined as maximum level in the first 24 h after surgery
AUC Cut-off Sensitivity Specificity
4 h after surgery
 0.861 0.15 0.83 66.7
0.3 0.67 0.76
2.0 0.33 0.98
Day 1 after surgery




 0.838 0.89 0.83 0.78
0.3 0.83 0.35
2.0 66.7 0.94
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However, etiologies and pathophysiology of AKI differ 
substantially between patient populations and, therefore, 
the performance of every biomarker in different patient 
cohorts and clinical settings may vary significantly 
requiring careful and specific evaluation of the marker 
in different scenarios. This also applies for G1 cell cycle 
arrest marker: IGFBP7 is superior to TIMP-2 in surgi-
cal patients whereas TIMP-2 is better for prediction of 
septic AKI, demonstrating that these two biomarkers are 
involved in slightly different pathways. Therefore, it is 
not clear whether the excellent results of the Discovery, 
Sapphire and Opal study can be transferred to patients 
undergoing CABG. Studies investigating the role of 
[TIMP-2]*[IGFBP7] in the prediction of AKI and defin-
ing cut-off values in cardiovascular patient populations 
are rare and currently restricted to adult and pediat-
ric open cardiac surgery. Meersch et al. investigated the 
diagnostic properties of these biomarkers for the detec-
tion of AKI in 50 patients undergoing CABG who were 
considered to be at high risk for impaired perioperative 
renal function assessed by the Cleveland Foundation 
Score [11]. Whereas diagnosis of AKI based on serum 
creatinine was delayed, TIMP-2 and IGFBP7 increased as 
early as 4 hours after surgery with a significant difference 
between patients with AKI and those without. The maxi-
mum urinary [TIMP-2]*[IGFBP7] value within the first 
24 h following CABG showed excellent diagnostic accu-
racy with an area under the receiver operating charac-
teristic curve of 0.84. Sensitivity was 0.92, and specificity 
was 0.81 for a cutoff value of 0.50. In addition, prediction 
of renal recovery from AKI was possible with urinary 
[TIMP-2]*[IGFBP7]. Comparable data were published 
from the same working group in a pediatric cardio surgi-
cal cohort (AUC 0.85, sensitivity 0.83, specificity 0.77 for 
cut-off 0.70 [(ng/ml)2/1000] [24].
The cut-off values defined in our study were slightly dif-
ferent from recently published studies In the Discovery, 
Sapphire and Opal study, best cut-off values for discrimi-
nation of patients with high risk for oncoming AKI was 
0.3 (ng/ml)2/1000 whereas Meersch set the value of 0.5 
(ng/ml)2/1000 for the adult and 0.70 (ng/ml)2/1000 for 
the pediatric cardiothoracic population. As mentioned 
above, etiologies and pathophysiology of AKI differ sub-
stantially between patient populations and therefore 
cut-off values from general surgical, septic, or medi-
cal patients might not be applicable to cardiothoracic 
patients.
Even comparing our results with other studies about 
the utility of urinary [TIMP–2]*[IGFBP7] for diagnosis 
of AKI after cardiac surgery may be difficult: Incidence 
of AKI was 52  % in the study from Meersch vs. 31.7  % 
in our study. In contrast, five patients suffered from AKI 
3 in our series compared to one in the cited trial. The 
incidence of AKI after cardiac surgery depends on the 
type of surgery varying significantly between isolated 
coronary artery bypass grafting, valvular surgery and 
being the highest for combined CABG+ valvular surgery. 
Merrsch included all types of cardio surgical procedures 
not giving any detailed information about performed 
procedures. In contrast, only isolated CABG procedures 
were included in our study. In addition, type of CBP and 
myocardial protection strategy might influence incidence 
as well as time onset of AKI.
If AKI is recognized early, nephroprotective measures 
can be considered to reduce exposure to renal insults and 
potentially avoid the development of higher stage AKI. 
Although the discussion about preventive or therapeutic 
interventions in critically ill patients with AKI is contro-
versial, there are some strategies that may be beneficial in 
the ICU setting: Although there are no specific therapies 
for AKI, the optimization of fluid balance and hemody-
namics as well as a medication review with avoidance of 
nephrotoxic drugs can reduce the incidence and severity 
of AKI and improve long-term outcomes [7]. This applies 
in particular for the subgroup of high risk patients that 
might be identified better with the cell cycle arrest mark-
ers. Accordingly, delayed consultation of a nephrologist 
is associated with higher mortality and increased dialysis 
dependence rates in critically ill AKI patients at hospi-
tal discharge [25]. In addition, earlier commencement of 
RRT in critically ill patients with incipient AKI may be 
beneficial with a reduction of mortality, in particular for 
patients after cardiac surgery [6, 26]. Preoperative remote 
ischemic preconditioning significantly reduced the rate of 
AKI and use of RRT in patients undergoing cardiac sur-
gery in a recently published multicenter randomized trial 
[27]. Therefore, our standard regime includes a bundle 
of interventions if [TIMP 2]*[IGFBP7] is higher than the 
reported cut-off value including consultation of a neph-
rologist, extensive chart review and stop of all nephro-
toxic agents, goal-directed hemodynamic management, 
delay—if possible—of any exposure to contrast agent, dis-
cussion of early RRT and delay of transferring the patient 
from the ICU to the normal ward. Therefore, urinary 
[TIMP-2]*[IGFBP7] might help to initiate established pre-
ventive and therapeutic interventions and investigate new 
concepts to prevent AKI.
Conclusion
Urinary [TIMP-2]*[IGFBP7] may be considered as early 
predictor of AKI after CABG surgery. It allows the iden-
tification of patients at high risk for the development of 
severe AKI, even with need for RRT, within the postop-
erative course. Urinary G1 cell cycle arrest biomarkers 
allow the diagnosis of AKI earlier than creatinine-based 
definition of AKI.
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Limitations
There are some limitations to our study. Due to the rela-
tively small sample size, the predicted cut-off values for 
[TIMP-2]*[IGFBP7] in the urine may be different from 
that obtained in other populations.
In the present study, the measurements of the biomark-
ers were conducted using the commercially available test 
kit, which only displayed the product of [TIMP-2] and 
[IGFBP7]. Therefore, we cannot draw any conclusions 
about the diagnostic properties of TIMP-2 and IGFBP7 
alone in comparison to their multiplication.
In the current study, urinary creatinine was not meas-
ured to estimate the true creatinine clearance for these 
patients. There are three major errors that can limit the 
accuracy of the creatinine clearance as an estimate of 
GFR: errors in urine collection; increases in both cre-
atinine secretion and extrarenal creatinine degrada-
tion as the GFR falls. Because of these limitations, we 
did not collect 24 h urine to calculate creatinine clear-
ance but used the Cockcroft–Gault formula to estimate 
GFR.
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